Cargando…
Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer
BACKGROUND: Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive and lethal disease, lacking effective therapeutic approaches. Available therapies only marginally prolong patient survival and are frequently coupled with severe adverse events. It is therefore pivotal to investigate novel and safe...
Autores principales: | Adamska, Aleksandra, Domenichini, Alice, Capone, Emily, Damiani, Verena, Akkaya, Begum Gokcen, Linton, Kenneth J., Di Sebastiano, Pierluigi, Chen, Xi, Keeton, Adam B., Ramirez-Alcantara, Veronica, Maxuitenko, Yulia, Piazza, Gary A., De Laurenzi, Vincenzo, Sala, Gianluca, Falasca, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681491/ https://www.ncbi.nlm.nih.gov/pubmed/31378204 http://dx.doi.org/10.1186/s13046-019-1308-7 |
Ejemplares similares
-
Inhibition of the Lysophosphatidylinositol Transporter ABCC1 Reduces Prostate Cancer Cell Growth and Sensitizes to Chemotherapy
por: Emmanouilidi, Aikaterini, et al.
Publicado: (2020) -
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
por: Adamska, Aleksandra, et al.
Publicado: (2017) -
Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers
por: Mattox, Tyler E., et al.
Publicado: (2019) -
Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell Proliferation and Colony Formation
por: Casari, Ilaria, et al.
Publicado: (2019) -
Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion
por: Whitt, Jason D., et al.
Publicado: (2016)